



REMARKS

The applicants have herein canceled the claims directed to compounds *per se*, leaving only claims directed to compositions comprising the recited compounds together with a pharmaceutically acceptable carrier, excipient, or diluent. Claim 25 has been amended to incorporate the genus of claim 1. It is noted that the particular compounds specifically excluded from claim 1 have been included in composition claim 25. Support for this amendment can be found, for example, in original claim 29, which was directed to pharmaceutical compositions comprising those compounds.

With regard to the restriction requirement, the applicants wish to accept the Examiner's invitation on page 5 of the Office Action and identify/elect a compound and build another group around it. For this purpose, the applicants elect compound 281:



and suggest the following genus:



wherein R₂₂, R₃₃, and R₄₄ are defined in the claims. The applicants respectfully submit that the special technical features shared by all the claims include (a) compounds of this structure and (b) the combination with a pharmaceutically acceptable carrier, excipient, or diluent, and that these special technical features distinguish the claimed compositions and methods over the prior art. For these reasons, therefore, the claimed compositions and methods comprising compounds of this genus are a single inventive concept.

If the examiner believes a teleconference will advance prosecution, he is encouraged to contact the undersigned as indicated below.

Respectfully submitted,

Date: October 12, 2006

/Michael S. Greenfield/
Registration No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606